Pitch Introduction
Scintiglo Shark Tank India presentation marked a significant moment for healthcare technology innovation in the country. Dr. Pankaj Parashar, founder of Categ Medical Devices Private Limited, entered the tank from Indore, Madhya Pradesh, with a mission to revolutionize early kidney disease detection. His portable diagnostic device promised to deliver laboratory-grade accuracy for urine testing in just two seconds, making healthcare accessible at the bottom of the pyramid. With 20 crore people in India suffering from kidney-related issues where symptoms often appear too late, Scintiglo aimed to bridge the critical gap between symptom onset and diagnosis. The pitch highlighted not just a business opportunity but a life-saving necessity for underserved populations who lack access to big laboratory infrastructure.
Business Overview
Scintiglo operates in the medical device sector, specifically focused on point-of-care diagnostics. The company has developed a proprietary device that detects microalbuminuria in urine, a critical early indicator of kidney disease, particularly in pregnant women suffering from pregnancy-induced hypertension. Unlike traditional laboratory setups requiring expensive machines costing ₹50-60 lakhs, Scintiglo’s device offers 95% accuracy at a fraction of the cost. The system includes a portable hardware device connected via Bluetooth to a smartphone application that generates formal PDF reports instantly. Currently deployed across approximately 70 laboratories, the company follows a unique rental-based service model rather than direct sales, making the technology accessible to small diagnostic centers and public health facilities.
| Company Attribute | Details |
|---|---|
| Legal Name | Categ Medical Devices Private Limited |
| Brand Name | Scintiglo |
| Founder | Dr. Pankaj Parashar |
| Founded Year | 2021 |
| Location | Indore, Madhya Pradesh |
| Industry | Medical Devices / Diagnostics |
About Founder’s
Dr. Pankaj Parashar brings a unique blend of medical expertise and engineering innovation to Scintiglo. A practicing doctor who also teaches at a medical college, Dr. Parashar developed an interest in medical technology during his undergraduate days. He pursued his passion by completing a PhD in Biomedical Engineering from IIT Delhi, giving him the technical foundation to develop complex diagnostic equipment. The inspiration for Scintiglo struck when his sister faced pregnancy-induced hypertension and required frequent protein testing. The inconvenience of traveling to laboratories repeatedly, combined with the realization that 50,000 women annually die from undetected preeclampsia in India, motivated him to create an accessible solution. His journey began with paper and post-it prototypes in January 2013, eventually evolving into a sophisticated medical device after seven years of rigorous development, regulatory clearances, and validation processes.
- Medical doctor with active teaching practice
- PhD in Biomedical Engineering from IIT Delhi
- Seven years of R&D experience in diagnostic technology
- Personal family experience drove product innovation
- Recipient of government grants and institutional support
Shark’s and Founder’s QnA
Namita Thapar: What is your current revenue?
Dr. Pankaj Parashar: We have actively been testing for three months now, and we have generated around ₹40,000 in revenue during this period.
Anupam Mittal: You mentioned you are in the middle of raising a larger round. Can you explain that?
Dr. Pankaj Parashar: Yes, we are already in discussions for a Series A round of approximately ₹7.5 crores. The investors have signed the term sheet and we were almost closing it last week. They said they can do this round, but for larger rounds, they look for industry validation.
Anupam Mittal: Let me tell you something about investments. They are digital, money doesn’t just appear in the bank. If you have approvals, certifications, and technical due diligence done, investors give money immediately. So why are you raising on Shark Tank?
Dr. Pankaj Parashar: I understand completely. However, we need to prove ourselves as a new company with a new medical device. The healthcare community requires higher standards, and we had difficulties initially convincing laboratories. We had to find opinion leaders in local markets to build trust.
Anupam Mittal: How much does it cost to make one machine?
Dr. Pankaj Parashar: It costs approximately ₹20,000 to manufacture one device.
Anupam Mittal: And how much security deposit do you take from labs?
Dr. Pankaj Parashar: We take a refundable security deposit of ₹20,000.
Anupam Mittal: Then why do you need money if the deposit covers your machine cost?
Dr. Pankaj Parashar: Sir, we started with 17 installations and faced many difficulties initially. We need funds for sales expansion and R&D. We are developing versions for respiratory care, tuberculosis care, and a home healthcare version priced around ₹5,000.
Vineeta Singh: Do small diagnostic labs currently outsource this test?
Dr. Pankaj Parashar: Yes, currently small labs outsource to big labs because the test costs ₹600 and requires expensive machines. Doctors hesitate to write this prescription because it is not available everywhere. With our solution, we offer 30% lower pricing and instant reports compared to next-day delivery from big labs.
Vineeta Singh: How does the reporting work?
Dr. Pankaj Parashar: The PDF report generates immediately on the smartphone app. Labs can print it on their letterhead instantly. We operate on a postpaid model like phone connections. Labs pay only for the tests conducted at month-end automatically through BharatPe integration.
Namita Thapar: What is inside the device that determines the results?
Dr. Pankaj Parashar: It is a trade secret. The reagents are calibrated specifically for this hardware to complete the reaction and read it optically within the specific time frame.
Namita Thapar: I want to make you an offer. I understand this industry, and honestly, money is not the motivation here. Penetration in small cities and convincing doctors requires credibility and navigating CDSCO regulations is not easy. I am doing this not for money but because it will benefit the bottom of the pyramid. However, I do not think a pre-revenue company should have a ₹75 crore valuation. I offer ₹50 lakhs for 10% equity and ₹25 lakhs debt at 12% interest.
Dr. Pankaj Parashar: Thank you for the offer.
Peyush Bansal: I think Namita can help you more than I can in this specific industry. If you do not take her offer, I might come back in, but for now, I am out.
Dr. Pankaj Parashar: I understand.
Aman Gupta: I would take 30% of the company, but since your existing investors have already given you a good valuation, I respect that and I am out.
Dr. Pankaj Parashar: Thank you.
Dr. Pankaj Parashar: Can I counter with 15% equity?
Namita Thapar: We were discussing 15%, but because your purpose is very good, I will help you without any equity stake. I will connect you with my medical team and provide support without investment.
Dr. Pankaj Parashar: I respectfully decline. The purpose of my hard work and double shifts is not money but a bigger purpose. We are individualizing products in healthcare which has not happened before. This is the time to take maximum risk when we have the potential to be a unicorn.
Namita Thapar: I understand. I wish you all the best.
Key Stats & Financials
Scintiglo presented itself as a pre-revenue stage company with minimal early traction but ambitious valuation expectations. The financial metrics revealed the challenges of hardware startups in the medical sector, where regulatory approvals and validation require significant upfront investment before revenue generation begins.
- Sales: ₹40,000 generated in first 3 months of active operations
- Device Manufacturing Cost: ₹20,000 per unit
- Revenue Model: ₹200 per test charge to partner laboratories
- Security Deposit: ₹20,000 refundable deposit per device installation
- Active Installations: 70 laboratories at time of pitch
| Financial Parameter | Amount / Details |
|---|---|
| Original Ask | ₹75 Lakhs for 1% Equity |
| Valuation Requested | ₹75 Crore |
| Revenue (3 months) | ₹40,000 |
| Cost Per Device | ₹20,000 |
| Price Per Test | ₹200 |
| Outstanding Round | ₹7.5 Crore (Term sheet signed) |
Business Potential and TAM
The addressable market for Scintiglo spans multiple healthcare segments with significant expansion potential. With 20 crore Indians at risk of kidney disease and 50,000 annual maternal deaths due to undetected preeclampsia, the clinical need is substantial. The device targets the bottom-of-pyramid population that remains unserved by traditional diagnostic infrastructure. Beyond nephrology, the technology platform extends to respiratory care, tuberculosis detection, and home healthcare monitoring. The public healthcare system represents a massive opportunity where portable, accurate diagnostics can transform primary health centers. Additionally, the planned home healthcare version at ₹5,000 price point opens the direct-to-consumer market, enabling chronic disease patients to monitor conditions without frequent hospital visits.
- Primary Market: Small diagnostic laboratories and clinics
- Secondary Market: Public health centers and government programs
- Tertiary Market: Home healthcare and individual consumers
- Expansion Areas: Respiratory and tuberculosis care diagnostics
- Geographic Focus: Tier 2, Tier 3 cities and rural India
Scintiglo: Ideal Target Audience & Demographics
| Demographic | Details |
|---|---|
| Primary Users | Pregnant women with hypertension risk |
| Secondary Users | Diabetic patients requiring regular monitoring |
| Facility Type | Small diagnostic labs (70+ partners) |
| Economic Segment | Bottom of pyramid, price-sensitive markets |
| Geographic Focus | Indore and expanding to tier-2/3 cities |
| Decision Makers | Lab owners, doctors, public health officials |
Marketing and Distribution Strategy
Scintiglo employs a B2B rental service model rather than equipment sales, reducing barrier to entry for small laboratories. The company identifies opinion leaders in local medical communities to build credibility and drive adoption among skeptical healthcare providers. The distribution strategy leverages a refundable security deposit system paired with per-test charging, aligning company success with laboratory utilization rates. Digital integration through the smartphone app enables instant report generation and BharatPe payment processing, streamlining operations for partner labs. Future roadmap includes expanding beyond kidney diagnostics into respiratory care, developing a ₹5,000 home-use device, and penetrating public healthcare systems where portability and affordability create maximum impact.
- Rental Model: ₹20,000 refundable deposit with per-test revenue
- Opinion Leader Strategy: Converting local medical influencers first
- Digital Reports: PDF generation on lab letterheads via smartphone app
- Payment Integration: Automated billing through BharatPe
- Product Pipeline: Home healthcare version at ₹5,000 price point
Scintiglo Deal Outcome
Despite strong interest from Namita Thapar and conditional interest from Peyush Bansal, Scintiglo left the tank without accepting any investment. Namita offered ₹50 lakhs for 10% equity combined with ₹25 lakhs debt at 12% interest, significantly diluting the founder compared to his original ask of 1% for ₹75 lakhs. Dr. Parashar countered with 15% equity for the total ₹75 lakh investment. When Namita declined the counter and offered mentorship without equity instead, the entrepreneur chose to decline all offers, citing alignment with existing investors who had already signed term sheets at the ₹75 crore valuation. Aman Gupta and Peyush Bansal stepped out citing valuation concerns and respect for existing investor commitments.
| Shark | Offer Made | Final Status |
|---|---|---|
| Namita Thapar | ₹50L equity + ₹25L debt @ 12% for 10% | Declined |
| Peyush Bansal | Conditional re-entry if Namita declined | Out |
| Aman Gupta | Would take 30% but respected valuation | Out |
| Ashneer Grover | No offer made | Out |
| Vineeta Singh | No offer made | Out |
Scintiglo Post-Show Update
Following the Shark Tank India appearance, Scintiglo continued its mission to democratize diagnostic healthcare access. The company maintained its focus on expanding installations beyond the initial 70 laboratories while pursuing the planned ₹7.5 crore Series A funding round that was in progress during the pitch. Dr. Parashar leveraged the national visibility to strengthen partnerships with public health departments and expand the technology platform into respiratory and tuberculosis care verticals as outlined during his presentation.
Business Analysis & Lessons
The Scintiglo pitch illustrates the tension between social impact and commercial valuation in healthcare startups. Dr. Parashar’s unwavering commitment to his ₹75 crore valuation, backed by existing investor term sheets, demonstrates the importance of founder conviction but also highlights potential pitfalls of overvaluation at pre-revenue stages. The rental-plus-consumables business model shows smart market entry strategy for expensive medical equipment in price-sensitive markets. However, the reluctance to accept dilution despite limited revenue validation suggests lessons about flexibility during early fundraising. The pitch underscores that in healthcare, regulatory approvals and clinical validation often precede revenue, making venture financing challenging but critical for scaling life-saving technologies.
- Valuation realism is crucial when revenue validation is minimal
- Rental models reduce customer acquisition barriers in B2B medical devices
- Existing investor commitments can create inflexibility in new negotiations
- Social impact alone may not justify premium valuations for investors
- Technical trade secrets provide defensibility but require clear IP protection
Pitch Conclusion
Scintiglo Shark Tank India episode highlighted both the potential and challenges of medical device entrepreneurship in India. While the companyfailed to secure a deal due to valuation mismatches, the pitch successfully showcased innovative technology addressing critical healthcare gaps. Dr. Pankaj Parashar’s dedication to serving bottom-of-pyramid populations while building a potentially unicorn-scale business represents the ambitious intersection of social impact and commercial healthcare innovation. For entrepreneurs watching, the episode demonstrates that investor alignment on valuation and stage-appropriate expectations remain crucial for funding success, even when the technology serves a clear humanitarian need.